CTLA-4 Recombinant Protein Cat. No.: 97-040

Availability: In stock

$0.00

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Rat
SOURCE SPECIES:HEK293 cells
SEQUENCE:Ile 38 - Asp 161
FUSION TAG:Fc Tag
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:This recombinant protein can be used for E, WB. For research use only.
BIOLOGICAL ACTIVITY: Measured by its binding ability in a functional ELISA. Immobilized Mouse B7-2, His Tag at 2 ug/mL (100 uL/well) can bind Rat CTLA-4, Fc Tag with a linear range of 0.2-6 ng/mL (QC tested).
psi-iconProperties
PURITY:>95% as determined by SDS-PAGE.

Endotoxin level is less than 1.0 EU per ug by the LAL method.
PREDICTED MOLECULAR WEIGHT:40.2 kDa
PHYSICAL STATE:Lyophilized
BUFFER:Tris with Glycine, Arginine and NaCl, pH7.5
STORAGE CONDITIONS:Lyophilized Protein should be stored at -20˚C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20˚C or -70˚C. Avoid repeated freeze-thaw cycles.
psi-iconAdditional Info
ALTERNATE NAMES:CTLA4,CD152,CELIAC3,GRD4,GSE,ICOS,IDDM12
ACCESSION NO.:Q62859
OFFICIAL SYMBOL:CTLA-4
GENE ID:63835
psi-iconBackground and References
BACKGROUND:CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152 (Cluster of differentiation 152), is a protein receptor that downregulates the immune system. CTLA4 is a member of the immunoglobulin superfamily, which is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. The protein contains an extracellular V domain, a transmembrane domain, and a cytoplasmic tail. Alternate splice variants, encoding different isoforms. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to CD80 and CD86, also called B7-1 and B7-2 respectively, on antigen-presenting cells. CTLA4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA4 is also found in regulatory T cells and may be important to their function. Fusion proteins of CTLA4 and antibodies (CTLA4-Ig) have been used in clinical trials for rheumatoid arthritis.
REFERENCES:1) Waterhouse P, et al., 1995, Science 270 (5238): 985–8.
2) Magistrelli G, et al., 1999. Eur. J. Immunol. 29 (11): 3596–602.
3) Rudd, CE. et al., 2009, Immunol. Rev. 229 (1): 12-26.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.